HCM — HUTCHMED (China) Share News
0.000.00%
Last trade - 00:00- £1.97bn
- £1.42bn
- $630.20m
REG - Hutchmed China Ltd - Overseas Regulatory Announcement
AnnouncementRCS - Hutchmed China Ltd - Completed Enrollment of Phase II/III Trial
AnnouncementRCS - Hutchmed China Ltd - Inclusion in National Reimbursement Drug List
AnnouncementREG - Hutchmed China Ltd - Overseas Regulatory Announcement
AnnouncementRCS - Hutchmed China Ltd - Clinical Data to be Presented at Congresses
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementREG - Hutchmed China Ltd - U.S. FDA Approval of FRUZAQLA™ (fruquintinib)
AnnouncementREG - Hutchmed China Ltd - Vesting of awards under the LTIP
AnnouncementRCS - Hutchmed China Ltd - Clinical Data to be Presented at ESMO 2023
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementRCS - Hutchmed China Ltd - NDA Submission for Fruquintinib in Japan
AnnouncementREG - Hutchmed China Ltd - Director’s Share Dealing
AnnouncementRCS - Hutchmed China Ltd - Phase IIIb Savolitinib Results at WCLC 2023
AnnouncementRCS - Hutchmed China Ltd - Patient Enrollment Completed for Bridging Study
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementRCS - Hutchmed China Ltd - BTD in China for Savolitinib for Gastric Cancer
AnnouncementREG - Hutchmed China Ltd - Sovleplenib Phase 3 Study Meets Primary Endpoint
AnnouncementREG - Hutchmed China Ltd - Exercise of Share Options by a Director
AnnouncementREG - Hutchmed China Ltd - Interim Results and Business Updates
Announcement